Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Recurrence/prognosis estimation using a molecularly positive surgical margin-based model calls for alternative curative strategies in pIIIA/N2 NSCLC.

Molecular oncology - 1 Jun 2024

Li Li, He Kewen, Zhou Tao, Xu Yang, Pang Jiaohui, Yu Qingxi, Gao Yongsheng, Shi Hongjin, Zhu He, Li Mengke, Yu Jinming, Yuan Shuanghu

Abstract excerpt

Stage pIIIA/N2 non-small cell lung cancer (NSCLC) is primarily treated by complete surgical resection combined with neoadjuvant/adjuvant therapies. However, up to 40% of patients experience tumor recurrence. Here, we studied 119 stage pIIIA/N2 NSCLC patients who received complete surgery plus adjuvant chemotherapy (CT) or chemoradiotherapy (CRT). The paired tumor and resection margin samples were analyzed using...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Disease-Free Survival

Share to High-Throughput Nucleotide Sequencing

Share to Lung Neoplasms

Share to Neoplasm Recurrence, Local

Share to Neoplasm Staging

Share to Prognosis

Source

Open in PubMed Open full text

Identifiers

PMID: 38327028
DOI: 10.1002/1878-0261.13600
PMCID: PMC11161728

Genes

ERBB2
SMARCA4

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 11 closest

Recurrence/prognosis estimation using a molecularly positive surgical margin-based model calls for alternative curative strategies in pIIIA/N2 NSCLC.PMID 38327028Read ↗

Clinical, Pathologic, and Molecular Prognostic Factors in Patients with Early-Stage EGFR-Mutant NSCLC.Semantic proximity Read ↗

Microscopic N2 disease exhibits a better prognosis in resected non-small-cell lung cancerSemantic proximity Read ↗

Clinical Impact of Genomic and Pathway Alterations in Stage I EGFR-Mutant Lung Adenocarcinoma.Semantic proximity Read ↗

A prognostic mutation panel for predicting cancer recurrence in stages II and III colorectal cancer.Semantic proximity Read ↗

Detection of oncogenic mutations in resected bronchial margins by next-generation sequencing indicates early relapse in stage IA lung adenocarcinoma patients.Semantic proximity Read ↗

Prognostic and therapeutic impact of RPN2-mediated tumor malignancy in non-small-cell lung cancer.Semantic proximity Read ↗

Development of a prognosis-prediction model incorporating genetic polymorphism with pathologic stage in stage I non-small cell lung cancer: A multicenter study.Semantic proximity Read ↗

Impact of DNA methylation on the recurrence risk of stage I non-small cell lung cancer with EGFR mutationsSemantic proximity Read ↗

The possibility of mutations of RAS signaling genes and/or TP53 in combination as a negative prognostic impact on pathological stage I non-small cell lung cancer.Semantic proximity Read ↗

CD44v6 downregulation as a prognostic factor for distant recurrence in resected stage I lung adenocarcinomasSemantic proximity Read ↗

Dual Specificity Phosphatase 6 (DUSP6) Polymorphism Predicts Prognosis of Inoperable Non-Small Cell Lung Cancer after Chemoradiotherapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.